Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism and Excretion of [14C] TQ-B3525 in Healthy Chinese Males
NCT05675202Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQ-B3525 in lymphoma and solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration at 336 hours, Area Under the Curve 0-t at 336 hours and 1 more. Status: unknown.
02
Drugs
TQ-B3525
03
Conditions
lymphomasolid tumor
Beyond the preview
Go deeper on NCT05675202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675202.